Manish Suresh Bhandare
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Manish Suresh Bhandare has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
Shailesh V. Shrikhande
24 shared publications- Shailesh Vinayak Shrikhande
Division of Gastrointestinal and Hepato-Pancreato-Biliary Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra 400012, India
24 shared publications - Vikram Chaudhari
Division of GI and HPB Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Parel, Mumbai, India
20 shared publications Vikram Chaudhari
18 shared publicationsAnant Ramaswamy
Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
10 shared publicationsVikas Ostwal
Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
9 shared publications
Latest Publications
- Open Access
- 12 May 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (8) , 6930-6932
Structured Adaptability in HPB Cancer Surgery: Precision Beyond Technical Uniformity
- 12 May 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (8) , 6930-6932
Open AccessStructured Adaptability in HPB Cancer Surgery: Precision Beyond Technical Uniformity
- 2 March 2026
- Published by Elsevier in Journal of Cancer Policy
- Vol. 48, 100730
Financial toxicity among gastric and pancreatic cancer survivors in India and its impact on quality of life
- 2 March 2026
- Published by Elsevier in Journal of Cancer Policy
- Vol. 48, 100730
Financial toxicity among gastric and pancreatic cancer survivors in India and its impact on quality of life
- Open Access
- 8 December 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 411 (1)
Outcomes of pancreatoduodenectomy in underlying liver cirrhosis: a single institution experience and literature review
Introduction Pancreatoduodenectomy (PD) is a complex procedure associated with up to 20–30% morbidity and 1–2% mortality. In the present study, we aimed to evaluate the outcomes of PD in patients with cirrhotic liver and assessed predictors of perioperative morbidity and mortality. Materials and methods This is a retrospective study from a prospectively maintained database. Amongst the patients who underwent PD between January 2013 till June 2024, only patients who had underlying cirrhotic liver were included in the study. Results A total of 24 patients were included. On binary logistic regression history of pancreatitis in the preoperative period (OD-25.8), stent block (OD-64.9), cholangitis (OD-273), and preoperative platelets less than 1.37(OD-40), preoperative INR more than 1.31(OD-40) and platelets count on POD1 less than 1.23 lakhs (OD-40) were associated with mortality. Conclusion Patients with clinically significant portal hypertension with thrombocytopenia and a deranged coagulation profile are associated with a high risk of mortality.
- 8 December 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 411 (1)
Open AccessOutcomes of pancreatoduodenectomy in underlying liver cirrhosis: a single institution experience and literature review
Introduction Pancreatoduodenectomy (PD) is a complex procedure associated with up to 20–30% morbidity and 1–2% mortality. In the present study, we aimed to evaluate the outcomes of PD in patients with cirrhotic liver and assessed predictors of perioperative morbidity and mortality. Materials and methods This is a retrospective study from a prospectively maintained database. Amongst the patients who underwent PD between January 2013 till June 2024, only patients who had underlying cirrhotic liver were included in the study. Results A total of 24 patients were included. On binary logistic regression history of pancreatitis in the preoperative period (OD-25.8), stent block (OD-64.9), cholangitis (OD-273), and preoperative platelets less than 1.37(OD-40), preoperative INR more than 1.31(OD-40) and platelets count on POD1 less than 1.23 lakhs (OD-40) were associated with mortality. Conclusion Patients with clinically significant portal hypertension with thrombocytopenia and a deranged coagulation profile are associated with a high risk of mortality.
- Open Access
- 12 July 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (10) , 1-3
ASO Author Reflections: Predictive Clinical Nomograms for Postoperative Outcomes Following Porto-Mesenteric Vein Resection with Pancreatectomy: Identifying the Best Patient for a High-Acuity Surgery
- 12 July 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (10) , 1-3
Open AccessASO Author Reflections: Predictive Clinical Nomograms for Postoperative Outcomes Following Porto-Mesenteric Vein Resection with Pancreatectomy: Identifying the Best Patient for a High-Acuity Surgery
- Open Access
- 5 July 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (10) , 7410-7421
Real-World Evidence of Porto-Mesenteric Vein Resections with Pancreatectomy and the Development of Predictive Clinical Nomograms for Postoperative Outcomes—An Analysis of 389 Cases: The “Porto-Mesenteric Vein Resection-Indian MulticentrE” (PRIME) Study
Background: With better surgery and chemotherapeutic agents, borderline resectable or locally advanced pancreatobiliary tumours are being treated with curative intent. This study presents real-world evidence of porto-mesenteric vein resections (PVR) with pancreatectomy and generates predictive nomograms for postoperative mortality (POM) and major complications (MC). Methods: A retrospective multicentre study, including 11 high-volume centres, evaluated patients undergoing PVR. Factors affecting 90-day POM and MC (Clavien-Dindo grades ≥ 3a) were assessed, and predictive nomograms were generated. Overall survival (OS) and disease-free survival (DFS) were estimated for patients with pancreatic ductal adenocarcinoma (PDAC). Cox regression analysis was performed to ascertain factors affecting OS and DFS. Results: Among 389 patients, POM was 6.4%, and MCs were 32.6%. Charlson comorbidity index > 4, preoperative biliary drainage, preoperative radiotherapy (PRT), segmental PVR, and additional organ resection (AOR) were predictive of POM. The independent predictors of MCs were American Society of Anesthesiologists status 3/4, PRT, and AOR. The generated model had an area under the curve (AUC) of 0.757, cutoff > 1.79 to predict POM, and AUC of 0.669, cutoff > 0.678 for MCs. In the 263 patients with PDAC, the median OS was 25.01 months (95% confidence interval [CI] 21.9–28.11), and DFS was 16.72 months (95% CI 14.56–18.89). Perineural invasion, segmental PVR, and margin positivity predicted worse survival, while completing multi-modality treatment was protective. Conclusions: The POM and MCs of PVR with pancreatectomy were at par with the world standards. The generated predictive nomograms for POM and MC revealed a good predictive potential. In patients with PDAC, completion of multimodality treatment offers better long-term survival.
- 5 July 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (10) , 7410-7421
Open AccessReal-World Evidence of Porto-Mesenteric Vein Resections with Pancreatectomy and the Development of Predictive Clinical Nomograms for Postoperative Outcomes—An Analysis of 389 Cases: The “Porto-Mesenteric Vein Resection-Indian MulticentrE” (PRIME) Study
Background: With better surgery and chemotherapeutic agents, borderline resectable or locally advanced pancreatobiliary tumours are being treated with curative intent. This study presents real-world evidence of porto-mesenteric vein resections (PVR) with pancreatectomy and generates predictive nomograms for postoperative mortality (POM) and major complications (MC). Methods: A retrospective multicentre study, including 11 high-volume centres, evaluated patients undergoing PVR. Factors affecting 90-day POM and MC (Clavien-Dindo grades ≥ 3a) were assessed, and predictive nomograms were generated. Overall survival (OS) and disease-free survival (DFS) were estimated for patients with pancreatic ductal adenocarcinoma (PDAC). Cox regression analysis was performed to ascertain factors affecting OS and DFS. Results: Among 389 patients, POM was 6.4%, and MCs were 32.6%. Charlson comorbidity index > 4, preoperative biliary drainage, preoperative radiotherapy (PRT), segmental PVR, and additional organ resection (AOR) were predictive of POM. The independent predictors of MCs were American Society of Anesthesiologists status 3/4, PRT, and AOR. The generated model had an area under the curve (AUC) of 0.757, cutoff > 1.79 to predict POM, and AUC of 0.669, cutoff > 0.678 for MCs. In the 263 patients with PDAC, the median OS was 25.01 months (95% confidence interval [CI] 21.9–28.11), and DFS was 16.72 months (95% CI 14.56–18.89). Perineural invasion, segmental PVR, and margin positivity predicted worse survival, while completing multi-modality treatment was protective. Conclusions: The POM and MCs of PVR with pancreatectomy were at par with the world standards. The generated predictive nomograms for POM and MC revealed a good predictive potential. In patients with PDAC, completion of multimodality treatment offers better long-term survival.
- Open Access
- 16 June 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 410 (1) , 1-9
Signet ring cell adenocarcinoma of the ampulla of Vater: does the presence of signet ring cells always suggest a poorer outcome?
Introduction Signet ring cell carcinoma (SRCC) of the ampulla of Vater is a rare histology with very limited data. In the present study, we report the outcomes of this rare pathology after pancreaticoduodenectomy from a single high-volume center. Materials and methods This is a retrospective study from a prospectively maintained database. All patients who presented to our tertiary cancer hospital with ampullary lesions and underwent pancreaticoduodenectomy between January 2017 and January 2024 were included. Results A total of 494 pancreaticoduodenectomies were performed during the study period for ampullary adenocarcinoma. Signet ring cells were present in 35 (7.1%). After propensity matching, the median OS in the signet ring group was not reached versus 55.7 months in the non-signet ring group (p-value-0.853) whereas the median DFS was 33.5 months in the non-signet ring group versus 18.2 months in the signet ring group (p-value-0.729). Conclusion The presence of signet ring cells on histology after curative pancreaticoduodenectomy for ampullary adenocarcinoma was not associated with poor outcomes. The percentage of signet ring cells also didn’t have any effect on survival.
- 16 June 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 410 (1) , 1-9
Open AccessSignet ring cell adenocarcinoma of the ampulla of Vater: does the presence of signet ring cells always suggest a poorer outcome?
Introduction Signet ring cell carcinoma (SRCC) of the ampulla of Vater is a rare histology with very limited data. In the present study, we report the outcomes of this rare pathology after pancreaticoduodenectomy from a single high-volume center. Materials and methods This is a retrospective study from a prospectively maintained database. All patients who presented to our tertiary cancer hospital with ampullary lesions and underwent pancreaticoduodenectomy between January 2017 and January 2024 were included. Results A total of 494 pancreaticoduodenectomies were performed during the study period for ampullary adenocarcinoma. Signet ring cells were present in 35 (7.1%). After propensity matching, the median OS in the signet ring group was not reached versus 55.7 months in the non-signet ring group (p-value-0.853) whereas the median DFS was 33.5 months in the non-signet ring group versus 18.2 months in the signet ring group (p-value-0.729). Conclusion The presence of signet ring cells on histology after curative pancreaticoduodenectomy for ampullary adenocarcinoma was not associated with poor outcomes. The percentage of signet ring cells also didn’t have any effect on survival.